{"id":3211,"date":"2025-04-09T07:00:00","date_gmt":"2025-04-09T07:00:00","guid":{"rendered":"https:\/\/parispresse.com\/europe-biosimilars-market-is-expected-to-reach-us-52-98-billion-by-2033\/"},"modified":"2025-04-09T07:00:00","modified_gmt":"2025-04-09T07:00:00","slug":"europe-biosimilars-market-is-expected-to-reach-us-52-98-billion-by-2033","status":"publish","type":"post","link":"https:\/\/parispresse.com\/en\/europe-biosimilars-market-is-expected-to-reach-us-52-98-billion-by-2033\/","title":{"rendered":"Europe biosimilars market is expected to reach US$ 52.98 billion by 2033"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\u00a0<\/div>\n


Europe biosimilars market – DataM Intelligence<\/span><\/a><\/p>\n<\/div>\n

(EMAILWIRE.COM<\/a>, April 09, 2025 ) Market Size
Europe biosimilars market size reached US$ 5.96 billion in 2024 and is expected to reach US$ 52.98 billion by 2033, growing at a CAGR of 27.7% during the forecast period 2025-2033.<\/p>\n

Download Free Sample: https:\/\/www.datamintelligence.com\/download-sample\/europe-biosimilars-market<\/a><\/p>\n

Market Dynamics
Expanding Biosimilar Approvals Fuel Europe\u0092s Biosimilars Market Growth
The increasing number of biosimilars receiving regulatory approval across key therapeutic areas\u0097such as oncology, autoimmune disorders, and diabetes\u0097is accelerating the growth of the biosimilars market in Europe. These alternatives offer significant cost savings compared to high-priced reference biologics, aligning with the region’s ongoing efforts to manage rising healthcare expenditures.<\/p>\n

This favorable environment is prompting more pharmaceutical companies to introduce biosimilars in European markets, further driving market expansion.<\/p>\n

For example, in January 2025, the European Medicines Agency\u0092s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued positive opinions recommending marketing authorizations for three biosimilars: Amgen\u0092s PAVBLU and SKOJOY, and CuraTeQ Biologics\u0092 DYRUPEG. In the same month, Celltrion launched STEQEYMA\u0097a biosimilar referencing STELARA (ustekinumab)\u0097in France, following earlier rollouts in Italy and Spain (January 2025), the U.K. (December 2024), and Germany and the Netherlands (November 2024).<\/p>\n

Read Our Report: https:\/\/www.datamintelligence.com\/research-report\/europe-biosimilars-market<\/a><\/p>\n

Market Segments
\u0095\tBy Product Type (Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Insulin, Anti-coagulants, Erythropoietin, Granulocyte Colony Stimulating Factor, Follitropin Interferons, Others),
\u0095\tBy Application (Oncology, Chronic Diseases, Autoimmune Diseases, Infectious Diseases, Growth Hormone Deficiency, Hematology, Others)<\/p>\n

Key Market Players
Key Players are Amgen Inc., Pfizer Inc., Sandoz Group AG, Teva Pharmaceuticals Inc., Biogen, Biocon Biologics Inc., Boehringer Ingelheim International GmbH, Samsung Biologics, Dr. Reddy\u0092s Laboratories Ltd and Fresenius Kabi AG. <\/div>\n


\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

\u00a0 Europe biosimilars market – DataM Intelligence (EMAILWIRE.COM, April 09, 2025 ) Market SizeEurope biosimilars market size reached US$ 5.96 billion in 2024 and is expected to reach US$ 52.98 billion by 2033, growing at a CAGR of 27.7% during the forecast period 2025-2033. Download Free Sample: https:\/\/www.datamintelligence.com\/download-sample\/europe-biosimilars-market Market DynamicsExpanding Biosimilar Approvals Fuel Europe\u0092s Biosimilars […]<\/p>\n","protected":false},"author":1,"featured_media":3212,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86,16],"tags":[],"class_list":{"0":"post-3211","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-press-releases"},"_links":{"self":[{"href":"https:\/\/parispresse.com\/en\/wp-json\/wp\/v2\/posts\/3211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/parispresse.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/parispresse.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/parispresse.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/parispresse.com\/en\/wp-json\/wp\/v2\/comments?post=3211"}],"version-history":[{"count":0,"href":"https:\/\/parispresse.com\/en\/wp-json\/wp\/v2\/posts\/3211\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/parispresse.com\/en\/wp-json\/wp\/v2\/media\/3212"}],"wp:attachment":[{"href":"https:\/\/parispresse.com\/en\/wp-json\/wp\/v2\/media?parent=3211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/parispresse.com\/en\/wp-json\/wp\/v2\/categories?post=3211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/parispresse.com\/en\/wp-json\/wp\/v2\/tags?post=3211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}